This mechanism disrupts downstream signalingpathway, ultimately inhibiting cancer cell proliferation. Sotorasib has transitioned from a clinical candidateto an approved therapy, demonstrating efficacy in treating patientswith KRas G12C mutated cancers, particularly nonsmall cell lung cancer(NSCLC). Here, KRAS is linked to non-small cell lung carcinoma.